```html

Zollinger‑Ellison Gastrinoma (Benign)

Overview

Zollinger‑Ellison syndrome (ZES) is a rare condition caused by a gastrin‑producing tumor called a gastrinoma. When the tumor is confined to the pancreas or duodenum and has not spread to distant organs, it is classified as benign. Gastrinomas secrete excess gastrin, which overstimulates stomach acid production, leading to severe peptic ulcer disease and other gastrointestinal problems.

Who it affects: ZES can occur at any age but most commonly presents in the 30‑ to 60‑year‑old range. Men and women are affected roughly equally, though some series report a slight male predominance (≈55 % male). About 20‑30 % of cases are associated with an inherited condition called multiple endocrine neoplasia type 1 (MEN‑1).

Prevalence: Gastrinomas are the most common functional neuroendocrine tumors of the pancreas, with an estimated incidence of 0.5–2 cases per million people per year (NIH). Because only a minority are malignant, benign gastrinomas represent roughly 10‑15 % of all reported gastrinomas.

Symptoms

Symptoms result from the combination of high gastric acid output and the local effects of the tumor itself. Not every patient experiences every symptom.

Gastrointestinal

• Refractory peptic ulcers: Multiple ulcers in the duodenum, jejunum, or stomach that do not heal with standard therapy.
• Abdominal pain: Crampy or burning pain, often worsened on an empty stomach.
• Diarrhea: Occurs in up to 50 % of patients; acid inactivates pancreatic enzymes, leading to fat malabsorption.
• Steatorrhea (fatty stools): Resulting from malabsorption of fats.
• Nausea & vomiting: May be triggered by ulcer complications or high acid load.
• Gastroesophageal reflux disease (GERD): Acid reflux can be severe.

Systemic

• Weight loss: Due to malabsorption, pain‑related anorexia, or chronic diarrhea.
• Fatigue or anemia: Chronic bleeding from ulcers can cause iron‑deficiency anemia.
• Rare hormonal symptoms: If the gastrinoma secretes other peptides (e.g., vasoactive intestinal peptide), patients may have flushing or watery diarrhea, but this is uncommon in isolated benign gastrinomas.

Causes and Risk Factors

Primary cause

The tumor arises from neuroendocrine (enterochromaffin‑like) cells of the pancreas or duodenum. Sporadic mutations in the MEN1 gene, RET, or other tumor‑suppressor genes can trigger uncontrolled gastrin production.

Risk factors

• Family history of MEN‑1: Inherited mutation dramatically increases risk (up to 60 % of carriers develop gastrinomas).
• Previous pancreatic or duodenal neuroendocrine tumor: Patients with a history of other NETs have a higher chance of developing gastrinoma.
• Smoking: Some data suggest a modestly increased risk for pancreatic neuroendocrine tumors.
• Chronic Helicobacter pylori infection: While H. pylori is not a direct cause, it can exacerbate ulcer disease, masking ZES.

Diagnosis

Diagnosing a benign gastrinoma involves confirming excess gastrin secretion, demonstrating high gastric acidity, and localizing the tumor.

Biochemical tests

• Fasting serum gastrin level: Values > 1,000 pg/mL (normal < 100 pg/mL) are highly suggestive, especially when accompanied by low gastric pH.
• Secretin stimulation test: In ZES, gastrin paradoxically rises > 120 pg/mL after IV secretin (a hormone that normally suppresses gastrin).
• Gastric pH measurement: A pH < 2 after an overnight fast confirms hyperacidity.

Imaging studies

• Endoscopic ultrasound (EUS): High‑resolution imaging of the pancreas and duodenum; sensitivity up to 85 % for tumors ≤ 2 cm.
• Multiphasic contrast CT or MRI: Provides anatomic detail and helps assess for metastasis.
• Somatostatin receptor scintigraphy (SRS) or Ga‑68 DOTATATE PET/CT: Detects neuroendocrine tissue via somatostatin receptors; valuable for locating small or occult lesions.

Pathology

If surgical removal is performed, histologic examination confirms the diagnosis and assesses for malignant features (vascular invasion, high Ki‑67 index). Benign gastrinomas typically show a Ki‑67 < 3 % and lack invasion.

Treatment Options

Management aims to control acid hypersecretion, remove or shrink the tumor, and monitor for recurrence.

Acid‑suppression medication

• High‑dose proton pump inhibitors (PPIs): Omeprazole 40‑80 mg daily or equivalent; most patients require lifelong therapy.
• H2‑receptor antagonists: May be added for breakthrough symptoms, but PPIs are preferred.

Surgical approaches (first‑line for localized benign tumors)

• Enucleation: Removal of the tumor while preserving surrounding tissue; suitable for small (< 2 cm), well‑circumscribed lesions.
• Pancreaticoduodenectomy (Whipple procedure): Reserved for larger or anatomically complex tumors.
• Laparoscopic or robotic techniques: Increasingly used for minimal postoperative pain and quicker recovery.

Non‑surgical options (when surgery is contraindicated)

• Endoscopic tumor ablation: Radiofrequency or laser ablation under EUS guidance.
• Somatostatin analogs (e.g., octreotide, lanreotide): Bind somatostatin receptors, decreasing gastrin release; useful as adjuncts or in patients with unresectable disease.
• Targeted therapy (everolimus, sunitinib): Mainly for metastatic disease, but may be considered in aggressive benign tumors that recur.

Lifestyle and supportive care

• Avoid NSAIDs, aspirin, and corticosteroids—these aggravate ulcer formation.
• Limit alcohol and caffeine, which stimulate acid secretion.
• Adopt a balanced, low‑fat diet to reduce diarrhea.
• Stay up‑to‑date with vaccinations (e.g., pneumococcal) if on long‑term immunosuppressive agents.

Living with Zollinger‑Ellison Gastrinoma (Benign)

Medication adherence

Take PPIs exactly as prescribed. Missing doses can quickly lead to breakthrough ulcer pain and bleeding.

Monitoring

• Serum gastrin levels every 6–12 months after surgery.
• Annual endoscopy if ulcers persist or if you have MEN‑1.
• Imaging (EUS or MRI) every 1–2 years to detect recurrence.

Dietary tips

• Eat small, frequent meals rather than large meals.
• Incorporate soluble fiber (e.g., oats, apples) to help with diarrhea.
• Stay hydrated—replace fluid losses from watery stools.

Managing diarrhea

Beyond diet, consider pancreatic enzyme replacement (creon) if fat malabsorption is significant. Discuss dosing with your gastroenterologist.

Psychosocial aspects

Chronic disease can be stressful. Support groups for neuroendocrine tumor patients and counseling services are valuable resources.

Prevention

Because gastrinomas arise from genetic mutations, primary prevention is limited. However, you can reduce overall risk and complications:

• For individuals with a known MEN1 mutation, engage in regular screening (annual gastrin level, periodic imaging) as recommended by a genetic counselor.
• Quit smoking and limit alcohol consumption.
• Eradicate H. pylori infection if present—testing is simple (breath test or stool antigen) and treatment reduces ulcer burden.
• Use acid‑suppressive therapy promptly if you develop persistent ulcer symptoms; early control prevents ulcer complications.

Complications

If untreated or poorly controlled, excess acid can cause serious problems:

• Perforated peptic ulcer: A medical emergency with a risk of peritonitis.
• Gastrointestinal bleeding: Can lead to anemia, transfusion dependence, or hemorrhagic shock.
• Gastric outlet obstruction: Chronic ulcer scarring narrows the pylorus.
• Malnutrition and osteoporosis: Chronic acid loss of calcium and vitamin D absorption.
• Transformation to malignant gastrinoma: Although rare for initially benign lesions, long‑term follow‑up is essential.

When to Seek Emergency Care

References

• Mayo Clinic. Zollinger‑Ellison syndrome. Accessed June 2026.
• National Institutes of Health (NIH). Pancreatic Neuroendocrine Tumors PDQ.
• American College of Gastroenterology. Guideline for Management of ZES, 2023.
• Cleveland Clinic. Zollinger‑Ellison Syndrome Overview.
• World Health Organization. Neuroendocrine Tumors Fact Sheet, 2022.

```